Chimerism of bone marrow mesenchymal stem/ stromal cells in allogeneic hematopoietic cell transplantation: Is it clinically relevant?

Yasuo Miura, Satoshi Yoshioka, Hisayuki Yao, Akifumi Takaori-Kondo, Taira Maekawa, Tatsuo Ichinohe

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Multipotent mesenchymal stem/stromal cells (MSCs) have been extensively used as a transplantable cell source for regenerative medicine and immunomodulatory therapy. Specifically in allogeneic hematopoietic stem cell transplantation (HSCT), co-transplantation or post-transplant infusion of MSCs derived from bone marrow (BM) of non-self donors has been implicated in accelerating hematopoietic recovery, ameliorating graft- vs.-host disease, and promoting tissue regeneration. However, irrespective of the use of MSC co-administration, post-transplant chimerism of BMderived MSCs after allogeneic HSCT has been reported to remain of host origin, suggesting that the infused donor MSCs are immunologically rejected or not capable of longterm engraftment in the host microenvironment. Also, hematopoietic cell allografts currently used for HSCT do not seem to contain sufficient amount of MSCs or their precursors to reconstitute host BM microenvironment. Since the toxic conditioning employed in allo-HSCT may impair the function of host MSCs to maintain hematopoietic/regenerative stem cell niches and to provide a local immunomodulatory milieu, we propose that new directions for enhancing immunohematopoietic reconstitution and tissue repair after allogeneic HSCT include the development of strategies to support functional replenishment of residual host MSCs or to support more efficient engraftment of infused donor MSCs. Future areas of research should include in vivo tracking of infused MSCs and detection of their microchimeric presence in extra-marrow sites as well as in BM.

Original languageEnglish
JournalChimerism
Volume4
Issue number3
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Chimerism
Cell Transplantation
Stem cells
Mesenchymal Stromal Cells
Bone
Hematopoietic Stem Cell Transplantation
Transplantation (surgical)
Transplants
Bone Marrow
Tissue regeneration
Poisons
Multipotent Stem Cells
Stem Cell Niche

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Molecular Biology
  • Genetics

Cite this

Chimerism of bone marrow mesenchymal stem/ stromal cells in allogeneic hematopoietic cell transplantation : Is it clinically relevant? / Miura, Yasuo; Yoshioka, Satoshi; Yao, Hisayuki; Takaori-Kondo, Akifumi; Maekawa, Taira; Ichinohe, Tatsuo.

In: Chimerism, Vol. 4, No. 3, 01.01.2013.

Research output: Contribution to journalReview article

Miura, Yasuo ; Yoshioka, Satoshi ; Yao, Hisayuki ; Takaori-Kondo, Akifumi ; Maekawa, Taira ; Ichinohe, Tatsuo. / Chimerism of bone marrow mesenchymal stem/ stromal cells in allogeneic hematopoietic cell transplantation : Is it clinically relevant?. In: Chimerism. 2013 ; Vol. 4, No. 3.
@article{3a3cde1573d6421fac9f7b0afd234ed2,
title = "Chimerism of bone marrow mesenchymal stem/ stromal cells in allogeneic hematopoietic cell transplantation: Is it clinically relevant?",
abstract = "Multipotent mesenchymal stem/stromal cells (MSCs) have been extensively used as a transplantable cell source for regenerative medicine and immunomodulatory therapy. Specifically in allogeneic hematopoietic stem cell transplantation (HSCT), co-transplantation or post-transplant infusion of MSCs derived from bone marrow (BM) of non-self donors has been implicated in accelerating hematopoietic recovery, ameliorating graft- vs.-host disease, and promoting tissue regeneration. However, irrespective of the use of MSC co-administration, post-transplant chimerism of BMderived MSCs after allogeneic HSCT has been reported to remain of host origin, suggesting that the infused donor MSCs are immunologically rejected or not capable of longterm engraftment in the host microenvironment. Also, hematopoietic cell allografts currently used for HSCT do not seem to contain sufficient amount of MSCs or their precursors to reconstitute host BM microenvironment. Since the toxic conditioning employed in allo-HSCT may impair the function of host MSCs to maintain hematopoietic/regenerative stem cell niches and to provide a local immunomodulatory milieu, we propose that new directions for enhancing immunohematopoietic reconstitution and tissue repair after allogeneic HSCT include the development of strategies to support functional replenishment of residual host MSCs or to support more efficient engraftment of infused donor MSCs. Future areas of research should include in vivo tracking of infused MSCs and detection of their microchimeric presence in extra-marrow sites as well as in BM.",
author = "Yasuo Miura and Satoshi Yoshioka and Hisayuki Yao and Akifumi Takaori-Kondo and Taira Maekawa and Tatsuo Ichinohe",
year = "2013",
month = "1",
day = "1",
doi = "10.4161/chim.25609",
language = "English",
volume = "4",
journal = "Chimerism",
issn = "1938-1956",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Chimerism of bone marrow mesenchymal stem/ stromal cells in allogeneic hematopoietic cell transplantation

T2 - Is it clinically relevant?

AU - Miura, Yasuo

AU - Yoshioka, Satoshi

AU - Yao, Hisayuki

AU - Takaori-Kondo, Akifumi

AU - Maekawa, Taira

AU - Ichinohe, Tatsuo

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Multipotent mesenchymal stem/stromal cells (MSCs) have been extensively used as a transplantable cell source for regenerative medicine and immunomodulatory therapy. Specifically in allogeneic hematopoietic stem cell transplantation (HSCT), co-transplantation or post-transplant infusion of MSCs derived from bone marrow (BM) of non-self donors has been implicated in accelerating hematopoietic recovery, ameliorating graft- vs.-host disease, and promoting tissue regeneration. However, irrespective of the use of MSC co-administration, post-transplant chimerism of BMderived MSCs after allogeneic HSCT has been reported to remain of host origin, suggesting that the infused donor MSCs are immunologically rejected or not capable of longterm engraftment in the host microenvironment. Also, hematopoietic cell allografts currently used for HSCT do not seem to contain sufficient amount of MSCs or their precursors to reconstitute host BM microenvironment. Since the toxic conditioning employed in allo-HSCT may impair the function of host MSCs to maintain hematopoietic/regenerative stem cell niches and to provide a local immunomodulatory milieu, we propose that new directions for enhancing immunohematopoietic reconstitution and tissue repair after allogeneic HSCT include the development of strategies to support functional replenishment of residual host MSCs or to support more efficient engraftment of infused donor MSCs. Future areas of research should include in vivo tracking of infused MSCs and detection of their microchimeric presence in extra-marrow sites as well as in BM.

AB - Multipotent mesenchymal stem/stromal cells (MSCs) have been extensively used as a transplantable cell source for regenerative medicine and immunomodulatory therapy. Specifically in allogeneic hematopoietic stem cell transplantation (HSCT), co-transplantation or post-transplant infusion of MSCs derived from bone marrow (BM) of non-self donors has been implicated in accelerating hematopoietic recovery, ameliorating graft- vs.-host disease, and promoting tissue regeneration. However, irrespective of the use of MSC co-administration, post-transplant chimerism of BMderived MSCs after allogeneic HSCT has been reported to remain of host origin, suggesting that the infused donor MSCs are immunologically rejected or not capable of longterm engraftment in the host microenvironment. Also, hematopoietic cell allografts currently used for HSCT do not seem to contain sufficient amount of MSCs or their precursors to reconstitute host BM microenvironment. Since the toxic conditioning employed in allo-HSCT may impair the function of host MSCs to maintain hematopoietic/regenerative stem cell niches and to provide a local immunomodulatory milieu, we propose that new directions for enhancing immunohematopoietic reconstitution and tissue repair after allogeneic HSCT include the development of strategies to support functional replenishment of residual host MSCs or to support more efficient engraftment of infused donor MSCs. Future areas of research should include in vivo tracking of infused MSCs and detection of their microchimeric presence in extra-marrow sites as well as in BM.

UR - http://www.scopus.com/inward/record.url?scp=84880753022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880753022&partnerID=8YFLogxK

U2 - 10.4161/chim.25609

DO - 10.4161/chim.25609

M3 - Review article

C2 - 23880502

AN - SCOPUS:84880753022

VL - 4

JO - Chimerism

JF - Chimerism

SN - 1938-1956

IS - 3

ER -